We report the case of a 56-year-old female with lipomatous hypertrophy of the pancreas. Abdominal CT and MRI showed fatty replacement over the entire pancreas. The pancreatic parenchyma was completely absent. ERCP showed no abnormal findings in the main pancreatic duct. EUS-FNA was performed to achieve a definitive diagnosis. Histological features of the FNA specimens revealed that adipose tissue generally replaced the pancreatic parenchyma, and pancreatic acini were identified with a scattered distribution. To consider the differential diagnosis of lipomatous pseudohypertrophy of the pancreas, it is necessary to distinguish it from obesity, diabetes, and age-related pancreatic fat infiltration and liposarcoma. By performing EUS-FNA, it was possible to obtain a definitive diagnosis in this patient. In conclusion, EUS-FNA may be helpful to make a definitive diagnosis in patients with lipomatous hypertrophy of the pancreas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12328-012-0318-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current drawbacks and future perspectives in the diagnosis and treatment of male factor infertility, with a focus on FSH treatment: an expert opinion.
J Endocrinol Invest
January 2025
Department of Medicine, University of Padova, Padua, Italy.
Purpose: Infertility is defined as the inability to conceive after 1 year of unprotected intercourse, affecting approximately 15-20% of couples in Western countries. It is a shared problem within the couple; when the main issue lies with one of the partners, it is preferable to refer to "male factor" or "female factor" infertility rather than simply male or female infertility. Despite male factor infertility accounting for half of all couple infertility cases, the clinical approach to the male partner is not uniformly standardized across international guidelines.
View Article and Find Full Text PDFCytologic diagnosis of fumarate hydratase-deficient renal cell carcinoma: A single-institutional experience.
Cancer Cytopathol
February 2025
Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Background: Fumarate hydratase-deficient renal cell carcinoma (FHRCC) is an aggressive carcinoma that typically presents as advanced-stage disease. Prompt recognition of FHRCC is critical for appropriate clinical care and genetic counseling for patients and family members. However, diagnosing FHRCC from cytology specimens is challenging, with limited characterization and no reports describing prospectively identified cases.
View Article and Find Full Text PDFAnatomic-Based Diagnosis and Filler Injection Techniques: Chin Augmentation and Jawline Contouring.
J Craniofac Surg
January 2025
Department of Oral Biology, Division in Anatomy and Developmental Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry.
Chin augmentation and jawline contouring have emerged as significant procedures in aesthetic medicine, addressing both structural and age-related changes in the lower face. This review explores anatomic-based diagnosis and filler injection techniques for these treatments. Ethnic variations in facial structure necessitate different approaches, with Western patients often seeking jawline definition, while Asian patients frequently require chin projection.
View Article and Find Full Text PDFA 63 year-Old Male With a Painful Subacute Demyelinating Neuropathy.
Neurohospitalist
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Subacute, painful weakness is a common problem encountered by neurologists and can be associated with systemic symptoms. The patient presented with 6 weeks of progressive neuropathic pain followed by sensory changes and distal-predominant weakness. This case reviews the broad differential for such a presentation and a comprehensive, stepwise approach to diagnosis.
View Article and Find Full Text PDFReal-World Evidence of the Impact of CanAssist Breast on Physician's Decision About the Use of Adjuvant Chemotherapy in Early Breast Cancer.
Cureus
December 2024
Medical Oncology, Healthcare Global Enterprises (HCG) Cancer Center, Bangalore, IND.
Background Clinicians use prognostic biomarker/multi-gene-based tests for predicting recurrence in hormone receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancer (EBC). CanAssist Beast (CAB) uses the expression of five protein biomarkers in combination with tumor-specific parameters such as tumor size, histopathological grade, and lymph node status to predict the risk of distant recurrence within five years of diagnosis for patients with HR+/HER2-, EBC. The current study aimed to evaluate the impact of prognostic tests on adjuvant chemotherapy decisions by assessing the agreement between clinical and CAB risk stratification as low-risk (LR) or high-risk (HR) for distant recurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!